As AstraZeneca keeps Tagrisso generics at bay, India grants patent for lung cancer drug nano-formulation
In what is being seen as a double blow to UK pharma major AstraZeneca's (LSE: AZN) non-small cell lung cancer (NSCLC) drug Tagrisso (osimertinib mesylate), the Indian Patent Office has granted a patent to the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, for its nano-formulation of drug osimertinib mesylate.
The patent grant comes months after the British drugmaker staved off severe generic competition from Alembic Pharma (BOM: 533573), India-based Cadila Healthcare's (BOM: 532321) US subsidiary, Zydus Pharma over the same patent, as well as Cadila Healthcare and MSN Laboratories.
The patent application has been cleared with nine claims filed by the NIPER, Hyderabad, for its nano-formulation which claims to address the risk of acquired resistance against the therapy in the first year of treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze